Literature DB >> 20880361

Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.

Daniel M Moreira1, Joseph C Presti, William J Aronson, Martha K Terris, Christopher J Kane, Christopher L Amling, Leon L Sun, Judd W Moul, Stephen J Freedland.   

Abstract

OBJECTIVES: We previously showed that prostate-specific antigen (PSA) nadir after radical prostatectomy (RP) significantly predicts biochemical recurrence (BCR). Herein, we sought to explore the effect of including PSA nadir into commonly used models on their accuracy to predict BCR after RP.
METHODS: This was a retrospective analysis of 943 and 1792 subjects from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Cancer (DPC) databases, respectively. The discrimination accuracy for BCR of seven previously published models was assessed using concordance index and compared with and without adding PSA nadir level in SEARCH. Using data from SEARCH, we developed a new nomogram incorporating PSA nadir to other known predictors (preoperative PSA, pathological Gleason score, PSA nadir level, surgical findings, prostate weight, body mass index and race) of BCR and externally validated it in the DPC.
RESULTS: In SEARCH, the mean concordance index across all seven nomograms was 0.687. After the inclusion of PSA nadir, the concordance index increased by nearly 7% (mean=0.753). The concordance index of the new nomogram in SEARCH was 0.779 (bias-corrected=0.767), which was 5% better than the next best model. In DPC, the new nomogram yielded a concordance index of 0.778.
CONCLUSION: The addition of postoperative PSA nadir to commonly used nomograms increased their accuracies by nearly 7%. Based upon this, we developed and externally validated a new nomogram, which was well calibrated and highly accurate, and is a potentially valuable tool for patients and physicians to predict BCR after RP.
© 2010 The Japanese Urological Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20880361      PMCID: PMC3188446          DOI: 10.1111/j.1442-2042.2010.02631.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  30 in total

1.  Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.

Authors:  Samson Shen; Herbert Lepor; Robert Yaffee; Samir S Taneja
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

2.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

Authors:  M W Kattan; J A Eastham; A M Stapleton; T M Wheeler; P T Scardino
Journal:  J Natl Cancer Inst       Date:  1998-05-20       Impact factor: 13.506

3.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.

Authors:  Stephen J Freedland; Elizabeth B Humphreys; Leslie A Mangold; Mario Eisenberger; Frederick J Dorey; Patrick C Walsh; Alan W Partin
Journal:  JAMA       Date:  2005-07-27       Impact factor: 56.272

4.  Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).

Authors:  Michel Bolla; Hein van Poppel; Laurence Collette; Paul van Cangh; Kris Vekemans; Luigi Da Pozzo; Theo M de Reijke; Antony Verbaeys; Jean-François Bosset; Roland van Velthoven; Jean-Marie Maréchal; Pierre Scalliet; Karin Haustermans; Marianne Piérart
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

5.  Evaluating the yield of medical tests.

Authors:  F E Harrell; R M Califf; D B Pryor; K L Lee; R A Rosati
Journal:  JAMA       Date:  1982-05-14       Impact factor: 56.272

6.  Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy.

Authors:  W W Roberts; E J Bergstralh; M L Blute; J M Slezak; M Carducci; M Han; J I Epstein; M A Eisenberger; P C Walsh; A W Partin
Journal:  Urology       Date:  2001-06       Impact factor: 2.649

7.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy.

Authors:  Andrew J Stephenson; Peter T Scardino; James A Eastham; Fernando J Bianco; Zohar A Dotan; Christopher J DiBlasio; Alwyn Reuther; Eric A Klein; Michael W Kattan
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

8.  Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

Authors:  J W Moul; R R Connelly; D P Lubeck; J J Bauer; L Sun; S C Flanders; G D Grossfeld; P R Carroll
Journal:  J Urol       Date:  2001-10       Impact factor: 7.450

9.  The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.

Authors:  Matthew R Cooperberg; David J Pasta; Eric P Elkin; Mark S Litwin; David M Latini; Janeen Du Chane; Peter R Carroll
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

10.  Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272

View more
  2 in total

1.  Prediction of biochemical failure using prostate-specific antigen half-life in patients with adverse pathologic features after radical prostatectomy.

Authors:  Kwang Suk Lee; Kyo Chul Koo; Byung Ha Chung
Journal:  World J Urol       Date:  2018-10-22       Impact factor: 4.226

2.  Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology.

Authors:  David H Wilson; David W Hanlon; Gail K Provuncher; Lei Chang; Linan Song; Purvish P Patel; Evan P Ferrell; Herbert Lepor; Alan W Partin; Dan W Chan; Lori J Sokoll; Carol D Cheli; Robert P Thiel; David R Fournier; David C Duffy
Journal:  Clin Chem       Date:  2011-10-13       Impact factor: 8.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.